<DOC>
	<DOCNO>NCT00444535</DOCNO>
	<brief_summary>This study examine efficacy safety lapatinib bevacizumab patient ErbB2-overexpressing breast cancer .</brief_summary>
	<brief_title>Lapatinib Bevacizumab Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Females least 18 year age . Women childbearing potential must negative serum pregnancy test screening . Documented evidence HER2overexpressing unresectable metastatic breast cancer . Disease may/may treat metastatic setting . Subjects permit ( require ) previouslytreated brain metastasis stable asymptomatic . Adequate hepatic , renal cardiac function ECOG score 01 life expectancy least 12 week . Able swallow oral medication Signed informed consent Exclusion criterion : Pregnancy Unstable symptomatic CNS metastasis Major surgery within 28 day enrollment ( minor surgery within 7 day ) . Prior anticancer treatment within 14 day enrollment , unresolved treatmentrelated toxicity . A serious nonhealing wound , ulcer , bone fracture baseline . Class II , III IV heart failure define NYHA functional classification system History significant vascular disease , arterial thrombosis , unstable INR , hypertensive crisis , uncontrolled hypertension . History myocardial infarction , stenting procedure , angioplasty within 6 month enrollment . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month enrollment . History malabsorption syndrome , ulcerative colitis , bowel obstruction . Proteinuria Requires concurrent anticancer treatment investigational treatment . Known hypersensitivity either study medication Received investigational treatment within 28 day 5 halflives , whichever longer Concurrent disease circumstance would lead investigator would consider subject inappropriate candidate study Requires medication exclude study participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>VEGF</keyword>
	<keyword>Tyrosine kinase</keyword>
	<keyword>ErbB2</keyword>
	<keyword>Her2-neu</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>ErbB1</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>lapatinib</keyword>
</DOC>